| scholarly article | Q13442814 |
| P50 | author | Igor Nikitin | Q56980284 |
| Robert Flisiak | Q56980311 | ||
| Patrick Marcellin | Q89798262 | ||
| Gregory J Dore | Q90411646 | ||
| Maria Buti | Q91265862 | ||
| Stefan Zeuzem | Q28360321 | ||
| Maria Beumont-Mauviel | Q47158921 | ||
| Fred Poordad | Q47412568 | ||
| P2093 | author name string | Oliver Lenz | |
| Maria Beumont-Mauviel | |||
| Monika Peeters | |||
| Michael Manns | |||
| Peter Ferenci | |||
| Goedele De Smedt | |||
| Ira Jacobson | |||
| Jane Scott | |||
| Leen Gilles | |||
| Michael W Fried | |||
| Morris Sherman | |||
| Vanitha Sekar | |||
| P2860 | cites work | Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C | Q73467050 |
| A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety | Q93603855 | ||
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 | ||
| In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor | Q24650264 | ||
| Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus | Q26830190 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 | ||
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus | Q28279955 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| Host genomics and HCV treatment response. | Q37932036 | ||
| Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow | Q37972768 | ||
| In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. | Q39736457 | ||
| Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study | Q42977630 | ||
| Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients | Q42992022 | ||
| Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | Q43032179 | ||
| SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders | Q43036959 | ||
| Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial | Q43041743 | ||
| Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study | Q47243589 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| ribavirin | Q421862 | ||
| pegylated interferon | Q7160835 | ||
| simeprevir | Q7517689 | ||
| P304 | page(s) | 1918-1929 | |
| P577 | publication date | 2013-10-11 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study | |
| P478 | volume | 58 |
| Q47548210 | A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. |
| Q40888934 | A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. |
| Q40784150 | A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines |
| Q38221090 | Antiviral therapy for chronic hepatitis C in 2014. |
| Q26851810 | Antiviral treatment of hepatitis C virus infection and factors affecting efficacy |
| Q42207125 | Antiviral treatment of hepatitis C. |
| Q38244931 | Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. |
| Q38204368 | Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir |
| Q34725990 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. |
| Q35854698 | Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study |
| Q34775524 | CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults |
| Q38217932 | CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy |
| Q38230357 | Cell and tissue engineering for liver disease |
| Q38403350 | Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation |
| Q91599703 | Changing Treatment Landscape of Hepatitis C Virus Infection Among Penitentiary Inmates |
| Q38838703 | Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment |
| Q37654449 | Chronic hepatitis C genotype 1 virus: who should wait for treatment? |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q28541762 | Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains |
| Q46661989 | Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity |
| Q42175896 | Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent |
| Q39153261 | Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection |
| Q38206573 | Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature |
| Q38208508 | Current status in the therapy of liver diseases |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q59360673 | Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world |
| Q35154587 | Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. |
| Q36327795 | Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients |
| Q38515906 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace |
| Q35905985 | Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection |
| Q35473208 | Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients |
| Q57389418 | Direct-acting antivirals for chronic hepatitis C |
| Q34557595 | Direct-acting antivirals for chronic hepatitis C. |
| Q40642039 | Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. |
| Q39010715 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? |
| Q28084266 | Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir |
| Q36668891 | Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting |
| Q38909432 | Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System |
| Q95812891 | Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C |
| Q41469651 | Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin |
| Q41160646 | Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure |
| Q28074783 | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis |
| Q37651899 | Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C |
| Q64104306 | Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q40291443 | Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study |
| Q26853642 | Emerging therapies for hepatitis C |
| Q35031753 | Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C |
| Q36148043 | Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. |
| Q41473188 | Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. |
| Q42220429 | Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. |
| Q34174207 | Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection |
| Q33424681 | Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. |
| Q35164782 | First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort |
| Q28552269 | Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents |
| Q40356056 | Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment |
| Q41666553 | Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism |
| Q40557598 | Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial |
| Q57168365 | HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies |
| Q30301355 | Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. |
| Q39305112 | Hepatitis B and C. |
| Q28084654 | Hepatitis C |
| Q26781984 | Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management |
| Q34298877 | Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection |
| Q34181683 | Hepatitis C Virus in Pregnancy and Early Childhood: Current Understanding and Knowledge Deficits |
| Q34439125 | Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review |
| Q26775815 | Hepatitis C genotype 4: The past, present, and future |
| Q41758808 | Hepatitis C in African Americans |
| Q30378509 | Hepatitis C treatment: where are we now? |
| Q34111759 | Hepatitis C virus NS3 mutations in haemophiliacs |
| Q26782033 | Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals |
| Q24628717 | Hepatitis C virus protease inhibitor-resistance mutations: our experience and review |
| Q27468916 | Hepatitis C virus: Promising discoveries and new treatments |
| Q42250363 | Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes |
| Q40827559 | IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. |
| Q97519947 | Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches |
| Q35501259 | Impact of all oral anti-hepatitis C virus therapy: A meta-analysis |
| Q40988716 | In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. |
| Q33717146 | Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. |
| Q59354172 | Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era |
| Q43100552 | Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals |
| Q42249679 | Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents. |
| Q91262277 | JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 |
| Q42244738 | JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1. |
| Q41429836 | Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). |
| Q40217467 | Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed |
| Q33390630 | Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination |
| Q38584289 | Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances |
| Q34143327 | Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. |
| Q36901167 | Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment |
| Q38215505 | NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. |
| Q33559298 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa |
| Q90086733 | New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials |
| Q33560181 | New Therapies for Hepatitis C Virus Infection |
| Q50283732 | New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014 |
| Q26800050 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review |
| Q45328037 | New hepatitis C antiviral treatments eliminate the virus |
| Q26795407 | New treatment strategies for hepatitis C infection |
| Q26853138 | New treatments for genotype 1 chronic hepatitis C - focus on simeprevir |
| Q45846064 | Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. |
| Q42231673 | Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies |
| Q38249065 | Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection |
| Q30418176 | PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients |
| Q30300424 | Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. |
| Q30365599 | Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents |
| Q38995225 | Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. |
| Q40671964 | Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin. |
| Q35370579 | Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis |
| Q30374727 | Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. |
| Q40533002 | Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing |
| Q26798477 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications |
| Q40771120 | Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. |
| Q36100521 | Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study |
| Q39398874 | Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients |
| Q53836297 | Recommendations on hepatitis C screening for adults. |
| Q38213847 | Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects |
| Q38206215 | Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. |
| Q38703524 | Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy |
| Q36874995 | Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy |
| Q38170161 | Role of IL28B for chronic hepatitis C treatment toward personalized medicine |
| Q41077060 | SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients |
| Q40539146 | Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. |
| Q41104105 | Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report |
| Q59355494 | Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis |
| Q38899447 | Significance of HCV RNA monitoring in the era of new potent therapies |
| Q42210312 | Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study |
| Q41752261 | Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study |
| Q41610311 | Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUES |
| Q40035445 | Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience |
| Q39968319 | Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation |
| Q33774821 | Simeprevir capsules |
| Q38216582 | Simeprevir for the treatment of chronic hepatitis C genotype 1 infection |
| Q38248210 | Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection |
| Q38247985 | Simeprevir for the treatment of hepatitis C virus infection |
| Q41613250 | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial |
| Q36391682 | Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study |
| Q36834349 | Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients |
| Q41680620 | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies |
| Q42211652 | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q42211649 | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial |
| Q33853210 | Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus |
| Q40923578 | Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation |
| Q38307580 | Simeprevir: a review of its use in patients with chronic hepatitis C virus infection |
| Q38167686 | Simeprevir: first global approval |
| Q38219424 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. |
| Q26770024 | Sofosbuvir treatment and hepatitis C virus infection |
| Q35037688 | Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis |
| Q38849917 | Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. |
| Q35903139 | Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype |
| Q39483711 | Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q38816811 | Targeting IFN-λ: therapeutic implications |
| Q36218266 | The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region |
| Q40340001 | The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings |
| Q39075044 | The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies |
| Q42220068 | The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. |
| Q38668968 | The role of HCV proteins on treatment outcomes |
| Q38197441 | The role of chemokines in hepatitis C virus-mediated liver disease |
| Q38206556 | The role of interferon in the new era of hepatitis C treatments |
| Q38174250 | Treating HCV in HIV 2013: on the cusp of change |
| Q38352572 | Treatment of chronic hepatitis C in patients with HIV/HCV coinfection |
| Q35880497 | Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors |
| Q41043113 | Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report |
| Q38263444 | Understanding the potential of hepatitis C virus internal ribosome entry site domains to modulate translation initiation via their structure and function. |
| Q45325544 | Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. |
| Q33890671 | Validation of the Fatigue Severity Scale in chronic hepatitis C. |
| Q42181383 | Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors |
| Q35592257 | Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study |
| Q38751552 | Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845. |
Search more.